Šalis: Izraelis
kalba: anglų
Šaltinis: Ministry of Health
BELZUTIFAN
MERCK SHARP & DOHME (ISRAEL - 1996) COMPANY LTD, ISRAEL
L01XX74
FILM COATED TABLETS
BELZUTIFAN 40 MG
PER OS
Required
MERCK SHARP & DOHME LLC, USA
BELZUTIFAN
For the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable or undesirable.
2023-07-17
Welireg ® 40 mg film-coated tablets (Belzutifan) PATIENT ALERT CARD IMPORTANT SAFETY INFORMATION PLEASE KEEP THIS CARD WITH YOU AT ALL TIMES • This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with WELIREG (belzutifan). • Show this card to any health care professional involved in your care. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Side effects can be reported to the Ministry of Health by using the link: https://sideeffects.health.gov.il Side effects can also be reported directly to MSD company on Tel: 09-9533333. By reporting side effects, you can help provide more information on the safety of this medicine. Welireg can cause low oxygen levels in your body that can be severe and may require you to stop treatment, receive oxygen therapy, or be hospitalized. This is called ‘hypoxia’. Your healthcare provider will monitor your oxygen levels before you start and during treatment with Welireg . CONTACT YOUR DOCTOR IMMEDIATELY IF YOU EXPERIENCE ANY OF THE FOLLOWING: • Difficulty breathing or shortness of breath • Increased heart rate • Rapid breathing • Feeling anxious or restless • Bluish discoloration of the skin and around your mouth • You are unable to complete sentences when at rest due to breathlessness • Unusual tiredness • Confusion IMPORTANT SAFETY INFORMATION FOR PATIENTS IF THESE SIGNS OR SYMPTOMS BECOME SEVERE OR ARE RAPIDLY WORSENING, THEN GO TO YOUR NEAREST EMERGENCY ROOM OR CALL 101 IMMEDIATELY TO SEEK MEDICAL ADVICE. IMPORTANT SAFETY INFORMATION PLEASE KEEP THIS CARD WITH YOU AT ALL TIMES • This patient alert card contains important safety information that you need to be aware of before, during, and after treatment with WELIREG (belzutifan). • Show this card to any health care professional involved in your care. • If you get any side effects, talk to your doctor, pharmacist or nurse. This i Perskaitykite visą dokumentą